BioSpace News Archive

Catalyst Pharmaceuticals, Inc. today announced that an abstract assessing the prevalence of Lambert-Eaton myasthenic syndrome (“LEMS”) among patients with small cell lung cancer (“SCLC”) in the United States.

Co-Diagnostics, Inc. announced that the Company will be hosting a booth this week at Asia Health/Medlab Asia 2023 from August 16-18 at the IMPACT Exhibition Center in Bangkok, Thailand.

Smart Scan Medical Imaging has opened its doors for business at 8307 Murphy Dr, Middleton.

Ipsen (Euronext: IPN; ADR: IPSEY) announced today approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP).

Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS) today reported financial results and operating highlights for the second quarter and six months ended June 30, 2023.

Gritstone bio, Inc. announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 32,500 shares of its common stock with an exercise price of $1.70, which is equal to the closing price of Gritstone’s common stock on August 7, 2023, the date of the grant.

LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023.

Kimball Electronics, Inc. announced financial results for the fourth quarter and fiscal year ended June 30, 2023.

Johnson & Johnson announced the final exchange ratio for its previously announced split-off exchange offer to Johnson & Johnson shareholders to exchange their shares of Johnson & Johnson for shares of common stock of Kenvue Inc. currently held by Johnson & Johnson.

EV Biologics Corp, OTC PINK:YECO, announced that it has completed production of a next-generation, “Gen-2", MSC exosome-based therapeutic product.